透景生命表示，本期受市场环境变化和集采政策推行等因素影响，主营业务收入有所下降。 北京商报讯（记者 丁宁）10月22日晚间，透景生命（300642）发布2025年第三季度报告显示，公司前 三季度实现营业收入2.58亿元，同比下降19.73%；归属净利润577.49万元，同比下降76.33%。 ...

证券日报网讯10月22日晚间，透景生命（300642）发布公告称，公司董事会同意聘任陈刚先生担任公司 副总经理。 ...

智通财经APP讯，透景生命(300642.SZ)发布2025年三季度报告，该公司前三季度营业收入为2.58亿元， 同比减少19.73%。归属于上市公司股东的净利润为577.49万元，同比减少76.33%。归属于上市公司股东 的扣除非经常性损益的净利润为137.32万元，同比减少90.45%。基本每股收益为0.0356元。 ...

Core Insights - The company reported a significant decline in revenue and net profit for the first three quarters of 2025, with total revenue at 258 million yuan, down 19.73% year-on-year, and net profit attributable to shareholders at 5.77 million yuan, down 76.33% year-on-year [1][2]. Financial Performance - Basic earnings per share for the reporting period were 0.04 yuan, with a weighted average return on equity of 0.38% [2]. - The company's gross margin for the first three quarters was 66.60%, an increase of 1.66 percentage points year-on-year, while the net margin was 1.10%, a decrease of 5.06 percentage points year-on-year [2]. - In Q3 2025, the gross margin improved to 68.11%, up 0.32 percentage points year-on-year and 0.68 percentage points quarter-on-quarter, while the net margin was 2.54%, down 12.85% year-on-year but up 1.05 percentage points quarter-on-quarter [2]. Expense Analysis - Total operating expenses for Q3 2025 were 148 million yuan, a decrease of 23.5 million yuan year-on-year, with an expense ratio of 57.37%, up 4.00 percentage points year-on-year [2]. - Breakdown of expenses showed a year-on-year decrease in sales expenses by 18.38%, while management expenses increased by 20.17%. R&D expenses decreased by 19.15%, and financial expenses decreased by 54.15% [2]. Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 18,800, an increase of 2,800 or 17.52% from the end of the previous half-year [2]. - The average market value of shares held per shareholder increased from 149,700 yuan at the end of the previous half-year to 204,000 yuan, a growth of 36.31% [2]. Company Overview - Shanghai TuoJing Life Technology Co., Ltd. was established on November 6, 2003, and went public on April 21, 2017. The company specializes in the R&D, production, and sales of in vitro diagnostic products under its own brand [3]. - The revenue composition of the company includes 92.50% from reagents, 6.20% from instruments, 1.26% from services, and 0.04% from materials [3]. - The company operates within the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics, and is involved in several concept sectors including gene sequencing and in vitro diagnostics [3].

透景生命10月22日公告，2025年第三季度实现营业收入9855.3万元，同比下降6.36%；归属于上市公司 股东的净利润301.57万元，同比下降83.02%；基本每股收益0.0186元。 前三季度实现营业收入2.58亿 元，同比下降19.73%；归属于上市公司股东的净利润577.49万元，同比下降76.33%；基本每股收益 0.0356元。 ...

人民财讯10月22日电，透景生命（300642）10月22日披露2025年三季度报告，公司第三季度实现营业收 入9855.3万元，同比下降6.36%；归母净利润301.57万元，同比下降83.02%。前三季度实现营业收入2.58 亿元，同比下降19.73%；归母净利润577.49万元，同比下降76.33%。 ...

Core Viewpoint - TuoJing Life reported a significant decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business performance [1] Financial Performance - Revenue for the first three quarters of 2025 was approximately 258 million yuan, representing a year-on-year decrease of 19.73% [1] - Net profit attributable to shareholders was around 5.77 million yuan, down 76.33% year-on-year [1] - Basic earnings per share were 0.0356 yuan, reflecting a decrease of 76.31% compared to the previous year [1] Market Position - As of the report date, TuoJing Life had a market capitalization of 4.2 billion yuan [1]

Group 1 - The core point of the article is that TuoJing Life (SZ 300642) held its fourth board meeting on October 22, 2025, to review the proposal for the third quarter report of 2025 [1] - TuoJing Life's revenue composition for the year 2024 is entirely from the in vitro diagnostics industry, accounting for 100.0% [1] - As of the report, TuoJing Life has a market capitalization of 4.2 billion yuan [1]

证券代码：300642 证券简称：透景生命 公告编号：2025-073 上海透景生命科技股份有限公司 关于聘任公司副总经理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陈刚先生：1966 年 10 月出生，中国国籍，无境外永久居留权，毕业于武汉 大学，硕士，中级工程师。现任中国医学装备协会病理装备分会常委，中国非公 立医疗机构协会病理学专委会常委，湖北省药物与医疗器械临床评价学会常务理 事。1997 年 7 月至 2012 年 12 月，就职于武汉人福医药集团股份有限公司，负 责多家子公司创建/中药、器械及商业板块 CEO；2013 年 2 月至 2016 年 6 月，任 武汉康录生物技术有限公司总经理；2016 年 6 月至今，任武汉康录生物技术股 份有限公司总经理、董事；2017 年 7 月至今，兼任武汉康录医学检验实验室有 限责任公司执行董事、经理、法定代表人。 截至本公告披露之日，陈刚先生未持有公司股份，与公司、公司控股股东、 实际控制人、持有公司 5%以上股份的股东以及其他董事、监事和高级管理人员 不存在关联关系；陈刚先生从未受过中国证监会 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-077 上海透景生命科技股份有限公司 2025 年第三季度报告披露的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"）于 2025 年 10 月 22 日召开第四届董事会第十四次会议和第四届监事会第十一次会议，审议并通过了 《关于公司 2025 年第三季度报告的议案》。为使投资者全面了解公司的经营成 果和财务状况，公司《2025 年第三季度报告》于 2025 年 10 月 23 日在中国证券 监督管理委员会指定的创业板信息披露网站巨潮资讯网上披露。 网址：http://www.cninfo.com.cn 敬请广大投资者注意查阅。 特此公告。 上海透景生命科技股份有限公司 董 事 会 2025 年 10 月 22 日 ...